No reviews yet. Be the first to rate Shigeki!
Chiba University scientists identify glutamine metabolism and lysosomal function as key vulnerabilities in drug-tolerant persister cells, offering new directions for KRAS-driven cancer treatment.
Chiba University researchers identify glutamine metabolism and lysosomal function as key vulnerabilities in drug-tolerant persister cells surviving KRAS inhibitor therapy, paving the way for combination strategies to reduce cancer relapse.
Photo by Mike Fox on Unsplash
Photo by Kristine Wook on Unsplash
Photo by Dan Gold on Unsplash
Photo by We-Vibe Toys on Unsplash
Photo by Nathan Anderson on Unsplash
Photo by Umanoide on Unsplash
Photo by Imani Bahati on Unsplash
Have a story or a research paper to share? Become an Expert Academic Contributor and publish your work on AcademicJobs.com.
Write news and research articles as a expert academic in your field publish your work on AcademicJobs.com
